london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

The use of biodegradable intravitreal implant of dexamethasone in the treatment of a patient with cystoid macular oedema (CMO) secondary to lower branch retinal vein occlusion (BRVO) - a case report

Poster Details

First Author: K.Michalska-Małecka POLAND

Co Author(s):    A. Kabiesz                  0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

This paper presents the results of using a biodegradable intravitreal implant of dexamethasone (Ozurdex) in a patient with cystoid macular oedema (CMO) secondary to branch retinal vein occlusion (BRVO).

Setting:

Ozurdex was administered in the Independent Public Clinical Hospital No 5 of Medical University of Silesia in Katowice.

Methods:

The diagnosis was based on examination of the eyes, extended by fluorescein angiography (AF) and optical coherence tomography (OCT). Injections of Ozurdex took place in the operating theatre, while respecting aseptic conditions and in accordance with the principles of intravitreal injections. From the onset of symptoms to the implantation passed the time of 4 weeks. Seven months after implantation, the patient noticed decreased visual acuity in the left eye: BCVA = 0.2. OCT showed a rebound increase in central retinal thickness: CRT = 749 µm. Since there were no contraindications (IOP = 16 mmHg), it was decided to qualify the patient for reimplantation of Ozurdex.

Results:

Before the Ozurdex implantation: BCVA = 0.1, NccOS = does not read, IOP = 15 mmHg and CRT 1,326 µm. At follow-up examination 14 days after the implantation, the patient did not report any adverse effects of the drug and improvement in visual acuity was 1 Snellen line. BCVA = 0.2, NccOS = does not read, IOP = 18 mm Hg. Repeated OCT showed reduced but persistent central retinal oedema: CRT = 1,061. Only 114 days after the implantation, did he present at the Hospital Outpatient Clinic. Ophthalmic examination of the Ozurdex-implanted eye revealed functional and morphological improvement in the retina. BCVA = 0.3, NccOS = D-3.0, IOP = 15 mmHg, CRT = 281 µm. Before reimplantation patient noticed decreased visual acuity in the left eye: BCVA = 0.2. OCT showed a rebound increase in central retinal thickness: CRT = 749 µm. 30 days after procedure, examination of the left eye showed: BCVA = 0.5, IOP = 16 and NccOS = D–1.5, CRT = 548 µm. After next 45 days, the patient reported further improvement in visual acuity: BCVA = 0.7, IOP = 16 mmHg and NccOS = D–0.75; CRT = 310 µm

Conclusions:

In the presented patient with CMO secondary to BRVO, the use of an intravitreal biodegradable implant containing dexamethasone (Ozurdex) resulted in improved visual acuity and reduced retinal oedema. The first implantation of a biodegradable implant containing dexamethasone resulted in partial

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy